Dr Sharon Discusses How Insurers Have Responded to the Availability of Therapies for RLS

In this video, Denise Sharon, MD, PhD, Clinical Director and Founding Partner, Comprehensive Sleep Medicine Center of the Gulf Coast, discusses how insurers have responded to the availability of therapies and changes in clinical practice guidelines for RLS.

Related Videos

Related Content

Advertisement

June 12th 2025

Immunotherapy Timing Does Not Significantly Affect Outcomes in ES-SCLC

Jared Kaltwasser

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC), a study found.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

June 6th 2025

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

Rose McNulty

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the CHALLENGE study recommended.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

June 6th 2025

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

Mary Caffrey

Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50. Obesity is among the factors linked to rising rates of cancer in young adults.

June 5th 2025

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

Rose McNulty

Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.

Related Content

Advertisement

June 12th 2025

Immunotherapy Timing Does Not Significantly Affect Outcomes in ES-SCLC

Jared Kaltwasser

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC), a study found.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

June 6th 2025

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

Rose McNulty

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the CHALLENGE study recommended.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

June 6th 2025

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

Mary Caffrey

Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50. Obesity is among the factors linked to rising rates of cancer in young adults.

June 5th 2025

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

Rose McNulty

Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.